Abstract:Introduction: Achieving an ideal Tc-99m labeled nitroimidazole hypoxia marker is still considered to be of great interest. Metronidazole xanthate (MNXT) ligand was synthesized and radiolabeled with Tc-99m-glucoheptonate (GH) to form the (TcO)-Tc-99m-MNXT complex, for the potential use as a novel probe for imaging tumor hypoxia. Methods: For labeling, (TcO)-Tc-99m-MNXT was prepared by ligand-exchange reaction with Tc-99m-GH. The radiochemical purity of the (TcO)-Tc-99m-MNXT complex was measured by thin layer chromatography (TLC) and high performance liquid chromatography (HPLC). The distribution coefficient and stability of the complex was investigated. The structure of the (TcO)-Tc-99m-MNXT complex was verified by preparation and characterization of the corresponding stable rhenium complex. The cellular uptake of the (TcO)-Tc-99m-MNXT complex was determined in murine sarcoma 5180 cell lines under hypoxic and aerobic conditions. The biodistribution and single photon emission computed tomography (SPECT) image studies of the (TcO)-Tc-99m-MNXT complex were performed in mice bearing S 180 tumor. Results: The radiochemical purity of the (TcO)-Tc-99m-MNXT complex was over 90%. It had good in vitro stability and its distribution coefficient indicated that it was a hydrophilic complex. When Tc-99m and Re complexes were coinjected in HPLC, both radioactivity (for Tc-99m complex) and UV detectors (for Re complex) showed nearly identical HPLC profiles, suggesting their structures are similar. The tumor cell experiment and the biodistribution in mice bearing S 180 tumor showed that the (TcO)-Tc-99m-MNXT complex had a good hypoxic selectivity and accumulated in the tumor with high uptake and good retention. Single photon emission computed tomography (SPE') image studies showed that the tumor detection was observable. Conclusions: (TcO)-Tc-99m-MNXT is prepared from a kit without the need for purification and shows high tumor uptake, tumor/blood and tumor/muscle ratios, suggesting that it would be a promising candidate for imaging tumor hypoxia. (C) 2015 Elsevier Inc. All rights reserved.

Synthesis and evaluation of [99mTcN]2+ core and [99mTcO]3+ core labeled complexes with 4-nitroimidazole xanthate derivative for tumor hypoxia imaging

Synthesis and evaluation of [<SUP>99m</SUP>TcN]<SUP>2+</SUP> core and [<SUP>99m</SUP>TcO]<SUP>3+</SUP> core labeled complexes with 4-nitroimidazole xanthate derivative for tumor hypoxia imaging

Radiosynthesis and Evaluation of Novel [99mtc(i)]+ and [99mtc(i)(co)3]+ Complexes with a 4‐nitroimidazole Isocyanide for Imaging Tumor Hypoxia

Synthesis and Biological Evaluation of Novel 99m Tc Labeled Ornidazole Xanthate Complexes As Potential Hypoxia Imaging Agents

Novel 99mtc Labelled Complexes with 2-Nitroimidazole Isocyanide: Design, Synthesis and Evaluation As Potential Tumor Hypoxia Imaging Agents.

Preparation and Bioevaluation of Novel 99Mtc-Labeled Complexes with a 2-Nitroimidazole HYNIC Derivative for Imaging Tumor Hypoxia

Synthesis And Biodistribution Of Novel Tc-99m Labeled 4-Nitroimidazole Dithiocarbamate Complexes As Potential Agents To Target Tumor Hypoxia

Kit formulation for preparation and biological evaluation of a novel 99m Tc-oxo complex with metronidazole xanthate for imaging tumor hypoxia

Preparation of two 99m Tc(CO) 3 labelled complexes with a 4-nitroimidazole isocyanide at different temperatures for molecular imaging of tumor hypoxia

99mTc labelled complexes with secnidazole xanthate: Synthesis and evaluation as potential radiotracers to target tumor hypoxia.

Preparation and biological evaluation of two novel 99mTc-nitrido complexes of metronidazole derivative for targeting hypoxia

Synthesis and Biological Evaluation of Novel 99Mtcn-Labeled Bisnitroimidazole Complexes Containing Monoamine-Monoamide Dithiol As Potential Tumor Hypoxia Markers

Preparation and Biological Evaluation of Two Novel Tc-99m-nitrido Complexes of Metronidazole Derivative for Targeting Hypoxia

Synthesis and Evaluation of <SUP>99m</SUP>Tc-Labelled 2-Nitroimidazole Derivatives with Different Linkers for Tumour Hypoxia Imaging

Synthesis, Radiolabeling and in Vivo Biological Evaluation of 99Mtc-Labeled MAG3-based Bisnitroimidazole Complexes As Tumor Hypoxia Markers

Biological Evaluation and SPECT Imaging of Tumor Hypoxia Using a Novel Technetium-99M Labeled Tracer with 2-Nitroimidazole Moiety

Preparation and Biological Evaluation of a Technetium-99M Labeled 4-Nitroimidazole Derivative for Imaging Tumor Hypoxia

In Vitro and in Vivo Evaluation of A Technetium-99m-Labeled 4-Nitroimidazole As A Tracer for Detection of Tumor Hypoxia

Preparation and bioevaluation of a novel 99m Tc-labelled propylene amine oxime (PnAO) containing two 4-methyl-2-nitroimidazole groups as a promising tumor hypoxia imaging agent

Synthesis and preliminary biological evaluation of the 99mTc labeled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers.

Development of (99m)Tc-N4-NIM for molecular imaging of tumor hypoxia